Evidence map›Paper›PMID 39047382›Full record

ArticleTranslational oncology2024

TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts.

Shin Takahashi, Nobuaki Sato, Kouji Kaneko, Norikazu Masuda, Masaaki Kawai, Hisashi Hirakawa, Tadashi Nomizu, Hiroji Iwata, Ai Ueda, Takashi Ishikawa and 27 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Clinical Relevance ofCancers · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Shin TakahashiDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan; Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Nobuaki SatoDepartment of Breast Oncology, Niigata Cancer Center Hospital, Niigata, Japan.
Kouji KanekoDepartment of Breast Oncology, Niigata Cancer Center Hospital, Niigata, Japan.
Norikazu MasudaDepartment of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Masaaki KawaiDepartment of Breast Surgery, Miyagi Cancer Center Hospital, Miyagi, Japan; Department of Surgery I, Yamagata University Graduate School of Medical Science, Yamagata, Japan.
Hisashi HirakawaDepartment of Surgery, Tohoku Kosai Hospital, Sendai, Japan.
Tadashi NomizuDepartment of Surgery, Hoshi General Hospital, Fukushima, Japan.
Hiroji IwataDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Ai UedaDepartment of Breast Oncology and Surgery, Tokyo Medical University Hospital, Tokyo, Japan.
Takashi IshikawaDepartment of Breast Oncology and Surgery, Tokyo Medical University Hospital, Tokyo, Japan.
Hiroko BandoBreast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Yuka InoueBreast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Takayuki UenoBreast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Shinji OhnoBreast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Makoto KuboDepartment of Breast Surgical Oncology, Kyushu University Hospital, Kyushu University, Fukuoka, Japan.
Hideko YamauchiDepartment of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan.
Masahiro OkamotoDepartment of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Eriko TokunagaDepartment of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Shunji KamigakiDepartment of Surgery, Sakai Municipal Hospital, Sakai, Japan.
Kenjiro AogiDepartment of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
Hideaki KomatsuDepartment of Surgery, Iwate Medical University School of Medicine, Shiwa, Japan.
Masahiro KitadaBreast Disease Center, Asahikawa Medical University Hospital, Asahikawa, Japan.
Yasuaki UemotoDepartment of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Tatsuya ToyamaDepartment of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yutaka YamamotoDepartment of Breast and Endocrine Surgery, Kumamoto University Hospital, Kumamoto, Japan.
Toshinari YamashitaDepartment of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Takehiro YanagawaDepartment of Breast Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Hiroko YamashitaDepartment of Breast Surgery, Hokkaido University Hospital, Sapporo, Japan.
Yoshiaki MatsumotoBreast Cancer Unit, Kyoto University Hospital, Graduate School of Medicine, Kyoto, Japan.
Masakazu ToiBreast Cancer Unit, Kyoto University Hospital, Graduate School of Medicine, Kyoto, Japan.
Minoru MiyashitaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takanori IshidaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Fumiyoshi FujishimaDepartment of Pathology, Tohoku University Hospital, Sendai, Japan.
Satoko SatoDepartment of Pathology, Tohoku University Hospital, Sendai, Japan.
Takuhiro YamaguchiDivision of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Fumiaki TakahashiDivision of Medical Engineering, Department of Information Science, Iwate Medical University, Yahaba, Japan.
Chikashi IshiokaDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan; Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: chikashi@tohoku.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TP53 signature is considered a predictor of neoadjuvant chemotherapy (NAC) response and prognostic factor in breast cancer. The objective of this study was to confirm TP53 signature can predict pathological complete response (pCR) and prognosis in cohorts of breast cancer patients who received NAC in prospective studies. Development cohorts (retrospective [n = 37] and prospective [n = 216] cohorts) and validation cohorts (NAC administered prospective study cohorts [n = 407] and retrospective perioperative chemotherapy (PC)-naïve, hormone receptor (HrR)-positive cohort [PC-naïve_HrR+ cohort] [n = 322]) were used. TP53 signature diagnosis kit was developed using the development cohorts. TP53 signature predictability for pCR and the relationship between recurrence-free survival (RFS), overall survival (OS), and the TP53 signature were analyzed. The pCR rate of the mutant (mt) signature group was significantly higher than that of the wild-type (wt) signature group (odds ratio, 5.599; 95 % confidence interval = 1.876-16.705; P = 0.0008). The comparison of the RFS and OS between the HrR+ and HER2- subgroup of the NAC cohort and of the PC-naïve_HrR+ cohort indicated that the RFS and OS benefit of NAC was greater in the mt signature group than in the wt signature group. From post hoc analyses, the RFS and OS benefit from adding capecitabine to FEC+T as NAC might be observed only in the mt signature group. The TP53 signature can predict the pCR after NAC, and the RFS and OS benefit from NAC may be greater in the mt signature group than in the wt signature group.

Indexed as

Breast cancerNeoadjuvant chemotherapyPathological complete responsePredictive factorTP53

Identifiers

PMID39047382
PMCPMC11325231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.